Key result
NT-proBNP, ST2, and galectin-3 correlate with reduced LVEF in breast cancer patients receiving anthracyclines.
Why the study?
Surveillance and management strategies during anthracycline therapy are limited by incomplete understanding of how cardiac biomarkers herald the onset of cardiotoxicity.
Do cardiac biomarkers and strain echocardiography correlate with subclinical cardiotoxicity in breast cancer patients receiving anthracyclines?
Comparison
Cardiac biomarkers and speckle tracking echocardiography at baseline, post-anthracycline, and 6 months post-anthracycline
Design
Prospective cohort study
Follow-up
6 months post-anthracycline chemotherapy
Authors
Loading...
May support biomarker and GLS monitoring for anthracycline cardiotoxicity risk; hypothesis-generating pending prospective validation.
Cohort (n=31)
Do cardiac biomarkers and strain echocardiography correlate with subclinical cardiotoxicity in breast cancer patients receiving anthracyclines?
Effect estimate: ρ = -0.45
p-value: p=0.019
Cardiac biomarkers including NT-proBNP, ST2, and galectin-3 correlate with reduced LVEF and subclinical cardiotoxicity in breast cancer patients receiving anthracycline therapy.
Bhagat et al. (2023) conducted a cohort in Breast cancer (n=31). Cardiac biomarkers (NT-proBNP, ST2, galectin-3) was evaluated on Temporal correlation between cardiac biomarkers and subclinical left ventricular dysfunction (ρ = -0.45, p=0.019). NT-proBNP, ST2, and galectin-3 correlated with reduced left ventricular ejection fraction in breast cancer patients receiving anthracyclines (baseline NT-proBNP ρ = -0.45; p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: